
Title:
Cefalexin
Text:


Beta-lactam antibiotic
.mw-parser-output .infobox-subbox{padding:0;border:none;margin:-3px;width:auto;min-width:100%;font-size:100%;clear:none;float:none;background-color:transparent}.mw-parser-output .infobox-3cols-child{margin:auto}.mw-parser-output .infobox .navbar{font-size:100%}body.skin-minerva .mw-parser-output .infobox-header,body.skin-minerva .mw-parser-output .infobox-subheader,body.skin-minerva .mw-parser-output .infobox-above,body.skin-minerva .mw-parser-output .infobox-title,body.skin-minerva .mw-parser-output .infobox-image,body.skin-minerva .mw-parser-output .infobox-full-data,body.skin-minerva .mw-parser-output .infobox-below{text-align:center}CefalexinClinical dataPronunciation/ˌsɛfəˈlɛksɪn/ Trade namesKeflex, Ceporex, others[1]Other namescephalexin (BAN UK), cephalexin (USAN US)AHFS/Drugs.comMonographMedlinePlusa682733License data
US DailyMed: Cephalexin
US FDA: Keflex
Pregnancycategory
AU: A[2]

Routes ofadministrationBy mouthDrug classFirst-generation cephalosporinATC codeJ01DB01 (WHO) QJ51DB01 (WHO)Legal statusLegal status
AU: S4 (Prescription only) 
UK: POM (Prescription only) 
US: ℞-only 
Pharmacokinetic dataBioavailabilityWell absorbedProtein binding15%Metabolism80% excreted unchanged in urine within 6 hours of administrationElimination half-lifeFor an adult with normal renal function, the serum half-life is 0.6–1.2 hours[3]ExcretionRenalIdentifiers
IUPAC name
(7R)-3-methyl-7-(α-D-phenylglycylamino)-3-cephem-4-carboxylic acid monohydrate
CAS Number15686-71-2 YPubChem CID2666IUPHAR/BPS4832DrugBankDB00567 YChemSpider25541 YUNII5SFF1W6677KEGGD00263 YChEBICHEBI:3534 YChEMBLChEMBL1727 YCompTox Dashboard (EPA)DTXSID9022780 ECHA InfoCard100.036.142 Chemical and physical dataFormulaC16H17N3O4SMolar mass347.39 g·mol−13D model (JSmol)Interactive imageMelting point326.8 °C (620.2 °F)
SMILES
O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)[C@@H](c3ccccc3)N)C)C(=O)O

InChI
InChI=1S/C16H17N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h2-6,10-11,15H,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1 YKey:ZAIPMKNFIOOWCQ-UEKVPHQBSA-N Y
.mw-parser-output .nobold{font-weight:normal}  (verify) 
Cefalexin, also spelled cephalexin, is an antibiotic that can treat a number of bacterial infections.[4] It kills gram-positive and some gram-negative bacteria by disrupting the growth of the bacterial cell wall.[4] Cefalexin is a beta-lactam antibiotic within the class of first-generation cephalosporins.[4] It works similarly to other agents within this class, including intravenous cefazolin, but can be taken by mouth.[5]
Cefalexin can treat certain bacterial infections, including those of the middle ear, bone and joint, skin, and urinary tract.[4] It may also be used for certain types of pneumonia, strep throat, and to prevent bacterial endocarditis.[4] Cefalexin is not effective against infections caused by methicillin-resistant Staphylococcus aureus (MRSA), most Enterococcus, or Pseudomonas.[4] Like other antibiotics, cefalexin cannot treat viral infections, such as the flu, common cold or acute bronchitis.[4] Cefalexin can be used in those who have mild or moderate allergies to penicillin.[4] However, it is not recommended in those with severe penicillin allergies.[4]
Common side effects include stomach upset and diarrhea.[4] Allergic reactions or infections with Clostridium difficile, a cause of diarrhea, are also possible.[4] Use during pregnancy or breast feeding does not appear to be harmful to the baby.[4][6][7] It can be used in children and those over 65 years of age.[4] Those with kidney problems may require a decrease in dose.[4]
Cefalexin was developed in 1967.[8][9][10] It was first marketed in 1969 and 1970 under the names Keflex and Ceporex, among others.[1][11] Generic drug versions are available under other trade names and are inexpensive.[4][12] It is on the World Health Organization's List of Essential Medicines.[13] In 2019, it was the 83rd most commonly prescribed medication in the United States, with more than 9 million prescriptions.[14][15] In Canada, it was the fifth most common antibiotic used in 2013.[16] In Australia, it is one of the top 15 most prescribed medications.[17]

Contents

1 Medical uses

1.1 Pregnancy and breastfeeding
1.2 Dogs


2 Adverse effects
3 Interactions
4 Pharmacology

4.1 Mechanism of action
4.2 Pharmacokinetics


5 Society and culture

5.1 Names


6 References
7 External links



Medical uses[edit]
  A course of cefalexin capsules, commonly prescribed for infections
Cefalexin can treat a number of bacterial infections including otitis media, streptococcal pharyngitis, bone and joint infections, pneumonia, cellulitis, and urinary tract infections.[4] It may be used to prevent bacterial endocarditis.[4] It can also be used for the prevention of recurrent urinary-tract infections.[4]
Cefalexin does not treat methicillin-resistant Staphylococcus aureus infections.[4]
Cefalexin is a useful alternative to penicillins in patients with penicillin intolerance. For example, penicillin is the treatment of choice for respiratory tract infections caused by Streptococcus, but cefalexin may be used as an alternative in penicillin-intolerant patients.[4] Caution must be exercised when administering cephalosporin antibiotics to penicillin-sensitive patients, because cross-sensitivity with beta-lactam antibiotics has been documented in up to 10% of patients with a documented penicillin allergy.[18]

Pregnancy and breastfeeding[edit]
It is pregnancy category B in the United States and category A in Australia, meaning that no evidence of harm has been found after being taken by many pregnant women.[4][6] Use during breast feeding is generally safe.[7]

Dogs[edit]
According to Plumb's Veterinary Medication Guides, cefalexin can be used in treating skin, respiratory tract, and urinary tract infections. The U.S. Food and Drug Administration (F.D.A.) has approved it for use in humans and dogs but not for other species. Like other drugs approved for human use, cefalexin  may be prescribed by veterinarians for animals in certain situations.[19]

Adverse effects[edit]
The most common adverse effects of cefalexin, like other oral cephalosporins, are gastrointestinal (stomach area) disturbances and hypersensitivity reactions.  Gastrointestinal disturbances include nausea, vomiting, and diarrhea, diarrhea being most common.[20]  Hypersensitivity reactions include skin rashes, urticaria, fever, and anaphylaxis.[4] Pseudomembranous colitis and Clostridium difficile have been reported with use of cefalexin.[4]
Signs and symptoms of an allergic reaction include rash, itching, swelling, trouble breathing, or red, blistered, swollen, or peeling skin. Overall, cefalexin allergy occurs in less than 0.1% of patients, but it is seen in 1% to 10% of patients with a penicillin allergy.[21]

Interactions[edit]
Like other β-lactam antibiotics, renal excretion of cefalexin is delayed by probenecid.[4] Alcohol consumption reduces the rate at which it is absorbed.[22] Cefalexin also interacts with metformin, an antidiabetic drug,[4] and this can lead to higher concentrations of metformin in the body.[4][23] Histamine H2 receptor antagonists like cimetidine and ranitidine may reduce the efficacy of cefalexin by delaying its absorption and altering its antimicrobial pharmacodynamics.[24]

Pharmacology[edit]
Mechanism of action[edit]
Cefalexin is a beta-lactam antibiotic of the cephalosporin family.[25]  It is bactericidal and acts by inhibiting synthesis of the peptidoglycan layer of the bacterial cell wall.[26] As cefalexin closely resembles d-alanyl-d-alanine, an amino acid ending on the peptidoglycan layer of the cell wall, it is able to irreversibly bind to the active site of PBP, which is essential for the synthesis of the cell wall.[26] It is most active against gram-positive cocci, and has moderate activity against some gram-negative bacilli.[4] However, some bacterial cells have the enzyme β-lactamase, which hydrolyzes the beta-lactam ring, rendering the drug inactive. This contributes to antibacterial resistance towards cefalexin.[27]

Pharmacokinetics[edit]
Cefalexin is rapidly and almost completely absorbed from the gastrointestinal tract with oral administration.[28] Absorption is slightly reduced when it is taken with food and the medication can be taken without regard for meals.[28] Peak levels of cefalexin occur about 1 hour after administration.[28] Maximal levels of cefalexin increase approximately linearly over a dose range of 250 to 1,000 mg.[28]
Like most other cephalosporins, cefalexin is not metabolized or otherwise inactivated in the body.[24][29]
The elimination half-life of cefalexin is approximately 30 to 60 minutes in people with normal renal function.[29][28] Therapeutic levels of cefalexin with oral administration are maintained for 6 to 8 hours.[28] For this reason, cefalexin is typically administered once every 6 to 12 hours depending on the indication.[28] More than 90% of cefalexin is excreted unchanged in the urine within 8 hours.[28]

Society and culture[edit]
It is on the World Health Organization's List of Essential Medicines, the safest and most effective medicines needed in a health system.[13] The World Health Organization classifies cefalexin as highly important for human medicine.[30]

Names[edit]
Cefalexin is the International Nonproprietary Name (INN) and Australian Approved Name (AAN), while cephalexin is the British Approved Name (BAN) and United States Adopted Name (USAN).[citation needed] Brand names for cefalexin include Keflex, Acfex, Cephalex, Ceporex, L-Xahl, Medoxine, Ospexin, and Torlasporin.[31] 

References[edit]
.mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-columns-2{column-width:30em}.mw-parser-output .reflist-columns-3{column-width:25em}.mw-parser-output .reflist-columns{margin-top:0.3em}.mw-parser-output .reflist-columns ol{margin-top:0}.mw-parser-output .reflist-columns li{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .reflist-upper-alpha{list-style-type:upper-alpha}.mw-parser-output .reflist-upper-roman{list-style-type:upper-roman}.mw-parser-output .reflist-lower-alpha{list-style-type:lower-alpha}.mw-parser-output .reflist-lower-greek{list-style-type:lower-greek}.mw-parser-output .reflist-lower-roman{list-style-type:lower-roman}

^ Jump up to: a b .mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:#d33}.mw-parser-output .cs1-visible-error{color:#d33}.mw-parser-output .cs1-maint{display:none;color:#3a3;margin-left:0.3em}.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}McPherson, Edwin M. (2007). Pharmaceutical Manufacturing Encyclopedia (3rd ed.). Burlington: Elsevier. p. 915. ISBN 9780815518563. Archived from the original on 8 September 2017.

^ "Cephalexin Use During Pregnancy". Drugs.com. 28 December 2018. Retrieved 7 February 2020.

^ McEvoy, G.K. (ed.). American Hospital Formulary Service — Drug Information 95. Bethesda, MD: American Society of Hospital Pharmacists, Inc., 1995 (Plus Supplements 1995)., p. 166

^ Jump up to: a b c d e f g h i j k l m n o p q r s t u v w x y z aa "Cephalexin". The American Society of Health-System Pharmacists. Archived from the original on 1 May 2014. Retrieved 21 April 2014.

^ Brunton, Laurence L. (2011). "53, Penicillins, Cephalosporins, and Other β-Lactam Antibiotics". Goodman & Gilman's pharmacological basis of therapeutics (12th ed.). New York: McGraw-Hill. ISBN 978-0071624428.

^ Jump up to: a b "Prescribing medicines in pregnancy database". Australian Government. 3 March 2014. Archived from the original on 8 April 2014. Retrieved 22 April 2014.

^ Jump up to: a b Wendy Jones (2013). Breastfeeding and Medication. Routledge. p. 227. ISBN 9781136178153. Archived from the original on 8 September 2017.

^ Hey, Edmund, ed. (2007). Neonatal formulary 5 drug use in pregnancy and the first year of life (5th ed.). Blackwell. p. 67. ISBN 9780470750353. Archived from the original on 8 September 2017.>

^ .mw-parser-output .citation{word-wrap:break-word}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}US patent 3275626, Robert B Morin & Billy G Jackson, "Penicillin conversion via sulfoxide", published 1966-09-27, issued 1966-09-27,  assigned to Eli Lilly and Co 

^ US patent 3507861, Robert B Morin & Billy G Jackson, "Certain 3-methyl-cephalosporin compounds", published 1970-04-21, issued 1970-04-21,  assigned to Eli Lilly and Co 

^ Ravina, Enrique (2011). The evolution of drug discovery : from traditional medicines to modern drugs (1. Aufl. ed.). Weinheim: Wiley-VCH. p. 267. ISBN 9783527326693. Archived from the original on 8 September 2017.

^ Hanlon, Geoffrey; Hodges, Norman (2012). Essential Microbiology for Pharmacy and Pharmaceutical Science. Hoboken: Wiley. p. 140. ISBN 9781118432433. Archived from the original on 8 September 2017.

^ Jump up to: a b World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

^ "The Top 300 of 2019". ClinCalc. Retrieved 16 October 2021.

^ "Cephalexin - Drug Usage Statistics". ClinCalc. Retrieved 16 October 2021.

^ "Human Antimicrobial Drug Use Report 2012/2013" (PDF). Public Health Agency of Canada (PHAC). November 2014. Archived (PDF) from the original on 21 March 2015. Retrieved 24 February 2015.

^ Australia's Health 2012: The Thirteenth Biennial Health Report of the Australian Institute of Health and Welfare. Australian Institute of Health and Welfare. 2012. p. 408. ISBN 9781742493053. Archived from the original on 8 September 2017.

^ "FDA Cephalexin drug label" (PDF). Archived (PDF) from the original on 18 April 2014. Retrieved 18 April 2014.

^ "Cephalexin". Plumb's Veterinary Drugs. Retrieved 2 April 2021.

^ "Cephalexin Side Effects". Drugs.com. Archived from the original on 8 February 2015. Retrieved 9 February 2015.

^ Haberfeld, H, ed. (2009). Austria-Codex (in German) (2009/2010 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 978-3-85200-196-8.

^ Barrio Lera JP, Alvarez AI, Prieto JG (June 1991). "Effects of ethanol on the pharmacokinetics of cephalexin and cefadroxil in the rat". Journal of Pharmaceutical Sciences. 80 (6): 511–6. doi:10.1002/jps.2600800602. PMID 1941538.

^ Jayasagar G, Krishna Kumar M, Chandrasekhar K, Madhusudan Rao C, Madhusudan Rao Y (2002). "Effect of cephalexin on the pharmacokinetics of metformin in healthy human volunteers". Drug Metabolism and Drug Interactions. 19 (1): 41–8. doi:10.1515/dmdi.2002.19.1.41. PMID 12222753. S2CID 26919498.

^ Jump up to: a b M. Lindsay Grayson (Editor in Chief) (2 October 2017). Kucers' The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition - Three Volume Set. CRC Press. pp. 364–. ISBN 978-1-4987-4796-7. {{cite book}}: |author1= has generic name (help)

^ Bothara SS, Kadam KR, Mahadik KG (2006). "Antibiotics". Principles of Medicinal Chemistry. Vol. 1 (14th ed.). Pune: Nirali Prakashan. p. 81. ISBN 8185790043.

^ Jump up to: a b Fisher JF, Meroueh SO, Mobashery S (February 2005). "Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunity". Chemical Reviews. 105 (2): 395–424. doi:10.1021/cr030102i. PMID 15700950.

^ Drawz SM, Bonomo RA (January 2010). "Three decades of beta-lactamase inhibitors". Clinical Microbiology Reviews. 23 (1): 160–201. doi:10.1128/CMR.00037-09. PMC 2806661. PMID 20065329.

^ Jump up to: a b c d e f g h "Cefalexin 500mg Tablets - Summary of Product Characteristics (SMPC) - (Emc)".

^ Jump up to: a b Linda Skidmore-Roth (16 July 2015). Mosby's Drug Guide for Nursing Students, with 2016 Update. Elsevier Health Sciences. pp. 181–. ISBN 978-0-323-17297-4.

^ World Health Organization (2019). Critically important antimicrobials for human medicine (6th revision ed.). Geneva: World Health Organization. hdl:10665/312266. ISBN 9789241515528. License: CC BY-NC-SA 3.0 IGO.

^ "Cefalexin International". Drugs.com. 3 February 2020. Retrieved 8 February 2020.


External links[edit]
"Cephalexin". Drug Information Portal. U.S. National Library of Medicine.
.mw-parser-output .navbox{box-sizing:border-box;border:1px solid #a2a9b1;width:100%;clear:both;font-size:88%;text-align:center;padding:1px;margin:1em auto 0}.mw-parser-output .navbox .navbox{margin-top:0}.mw-parser-output .navbox+.navbox,.mw-parser-output .navbox+.navbox-styles+.navbox{margin-top:-1px}.mw-parser-output .navbox-inner,.mw-parser-output .navbox-subgroup{width:100%}.mw-parser-output .navbox-group,.mw-parser-output .navbox-title,.mw-parser-output .navbox-abovebelow{padding:0.25em 1em;line-height:1.5em;text-align:center}.mw-parser-output .navbox-group{white-space:nowrap;text-align:right}.mw-parser-output .navbox,.mw-parser-output .navbox-subgroup{background-color:#fdfdfd}.mw-parser-output .navbox-list{line-height:1.5em;border-color:#fdfdfd}.mw-parser-output .navbox-list-with-group{text-align:left;border-left-width:2px;border-left-style:solid}.mw-parser-output tr+tr>.navbox-abovebelow,.mw-parser-output tr+tr>.navbox-group,.mw-parser-output tr+tr>.navbox-image,.mw-parser-output tr+tr>.navbox-list{border-top:2px solid #fdfdfd}.mw-parser-output .navbox-title{background-color:#ccf}.mw-parser-output .navbox-abovebelow,.mw-parser-output .navbox-group,.mw-parser-output .navbox-subgroup .navbox-title{background-color:#ddf}.mw-parser-output .navbox-subgroup .navbox-group,.mw-parser-output .navbox-subgroup .navbox-abovebelow{background-color:#e6e6ff}.mw-parser-output .navbox-even{background-color:#f7f7f7}.mw-parser-output .navbox-odd{background-color:transparent}.mw-parser-output .navbox .hlist td dl,.mw-parser-output .navbox .hlist td ol,.mw-parser-output .navbox .hlist td ul,.mw-parser-output .navbox td.hlist dl,.mw-parser-output .navbox td.hlist ol,.mw-parser-output .navbox td.hlist ul{padding:0.125em 0}.mw-parser-output .navbox .navbar{display:block;font-size:100%}.mw-parser-output .navbox-title .navbar{float:left;text-align:left;margin-right:0.5em}.mw-parser-output .navbar{display:inline;font-size:88%;font-weight:normal}.mw-parser-output .navbar-collapse{float:left;text-align:left}.mw-parser-output .navbar-boxtext{word-spacing:0}.mw-parser-output .navbar ul{display:inline-block;white-space:nowrap;line-height:inherit}.mw-parser-output .navbar-brackets::before{margin-right:-0.125em;content:"[ "}.mw-parser-output .navbar-brackets::after{margin-left:-0.125em;content:" ]"}.mw-parser-output .navbar li{word-spacing:-0.125em}.mw-parser-output .navbar a>span,.mw-parser-output .navbar a>abbr{text-decoration:inherit}.mw-parser-output .navbar-mini abbr{font-variant:small-caps;border-bottom:none;text-decoration:none;cursor:inherit}.mw-parser-output .navbar-ct-full{font-size:114%;margin:0 7em}.mw-parser-output .navbar-ct-mini{font-size:114%;margin:0 4em}vteAntibacterials active on the cell wall and envelope (J01C-J01D)Beta-lactams(inhibit synthesisof peptidoglycanlayer of bacterialcell wall by bindingto and inhibitingPBPs, a group ofD-alanyl-D-alaninetranspeptidases)Penicillins (Penams)Narrowspectrumβ-lactamase sensitive(1st generation)
Benzylpenicillin (G)#
Benzathine benzylpenicillin#
Procaine benzylpenicillin#
Phenoxymethylpenicillin (V)#
Propicillin‡
Pheneticillin‡
Azidocillin‡
Clometocillin‡
Penamecillin‡
β-lactamase resistant(2nd generation)
Cloxacillin# (Dicloxacillin
Flucloxacillin)
Oxacillin
Nafcillin
Methicillin‡
ExtendedspectrumAminopenicillins (3rd generation)
Amoxicillin#
Ampicillin# (Pivampicillin
Hetacillin‡
Bacampicillin‡
Metampicillin‡
Talampicillin‡)
Epicillin‡
Carboxypenicillins (4th generation)
Ticarcillin
Carbenicillin‡ / Carindacillin‡
Temocillin‡
Ureidopenicillins (4th generation)
Piperacillin
Azlocillin‡
Mezlocillin‡
Other
Mecillinam (Pivmecillinam)
Sulbenicillin‡
Carbapenems / Penems
Carbapenems (Ertapenem
Antipseudomonal (Doripenem
Imipenem
Meropenem)
Biapenem‡
Panipenem)
Penems (Faropenem
Ritipenem§)
CephemsCephalosporinsCephamycinsCarbacephems1st generation
Cefazolin#
Cefalexin #
Cefadroxil
Cefapirin
Cefazedone‡
Cefazaflur‡
Cefradine‡
Cefroxadine‡
Ceftezole‡
Cefaloglycin‡
Cefacetrile‡
Cefalonium‡
Cefaloridine‡
Cefalotin
Cefatrizine‡
2nd generation
Cefaclor
Cefprozil
Cefuroxime
Cefuroxime axetil
Cefamandole‡
Cefonicid‡
Ceforanide‡
Cefuzonam‡
Cephamycin (Cefoxitin
Cefotetan
Cefminox‡
Cefbuperazone‡
Cefmetazole‡)
Carbacephem (Loracarbef‡)
3rd generation
Cefixime#
Ceftriaxone#
Cefotaxime#
Antipseudomonal (Ceftazidime#
Cefoperazone‡)
Cefdinir
Cefcapene
Cefdaloxime
Ceftizoxime
Cefmenoxime
Cefpiramide
Cefpodoxime
Ceftibuten
Cefditoren
Cefotiam‡
Cefetamet‡
Cefodizime‡
Cefpimizole‡
Cefsulodin‡
Cefteram‡
Ceftiolene‡
Oxacephem (Flomoxef‡
Latamoxef‡)
4th generation
Cefepime
Cefozopran‡
Cefpirome
Cefquinome‡
5th generation
Ceftaroline fosamil
Ceftolozane
Ceftobiprole
Siderophore
Cefiderocol#
Veterinary
Ceftiofur
Cefquinome
Cefovecin
Monobactams
Aztreonam
Tigemonam‡
Carumonam‡
Nocardicin A‡
β-lactamase inhibitors
Penam (Sulbactam
Tazobactam)
Clavam (Clavulanic acid)
non-β-lactam (Relebactam
Avibactam
Vaborbactam)
Combinations
Amoxicillin/clavulanic acid#
Ampicillin/flucloxacillin
Ampicillin/sulbactam (Sultamicillin)
Benzathine benzylpenicillin/procaine benzylpenicillin
Cefoperazone/sulbactam
Ceftazidime/avibactam
Ceftolozane/tazobactam
Imipenem/cilastatin#
Imipenem/cilastatin/relebactam
Meropenem/vaborbactam
Panipenem/betamipron
Piperacillin/tazobactam
Ticarcillin/clavulanic acid
PolypeptidesGlycopeptides
Inhibit PG chain elongation: Vancomycin# (Oritavancin
Telavancin)
Teicoplanin (Dalbavancin)
Ramoplanin§
Ristocetin‡
Avoparcin
Lipopeptides
Insert into bacterial cell wall causing perforation and depolarization: Daptomycin
Surfactin
Polymyxins
Bind to LPS in the outer bacterial membrane, acting in detergent-like fashion: Colistin
Polymyxin B
Intracellular
Inhibit PG subunit synthesis and transport: NAM synthesis inhibition (Fosfomycin)
DADAL/AR inhibitors (Cycloserine)
bactoprenol inhibitors (Bacitracin)
Other
Hydrolyze NAM-NAG
lysozyme
Tyrothricin
Gramicidin
Tyrocidine
Isoniazid#
Teixobactin

#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III

.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;justify-content:center;align-items:baseline}.mw-parser-output .portal-bar-bordered{padding:0 2em;background-color:#fdfdfd;border:1px solid #a2a9b1;clear:both;margin:1em auto 0}.mw-parser-output .portal-bar-unbordered{padding:0 1.7em;margin-left:0}.mw-parser-output .portal-bar-header{margin:0 1em 0 0.5em;padding:0.2em 0;flex:0 0 auto;min-height:24px;line-height:22px}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0 1 auto;padding:0.15em 0;column-gap:1em}.mw-parser-output .portal-bar-item{display:flex;align-items:baseline;margin:0.15em 0;min-height:24px;text-align:left}.mw-parser-output .portal-bar-logo{width:22px;line-height:22px;margin:0 0.2em;text-align:right}.mw-parser-output .portal-bar-link{margin:0 0.2em;text-align:left}@media screen and (max-width:768px){.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;flex-flow:column wrap}.mw-parser-output .portal-bar-header{text-align:center;flex:0;padding-left:0.5em;margin:0 auto}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:baseline;flex:0;margin:0 auto;column-gap:1em;border-top:1px solid #a2a9b1}}.mw-parser-output .navbox+link+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .navbox+style+.portal-bar-bordered{margin-top:-1px}.mw-parser-output .portal-bar+.navbox-styles+.navbox{margin-top:-1px}Portal:Medicine





